Australia markets closed
  • ALL ORDS

    7,339.30
    -52.40 (-0.71%)
     
  • AUD/USD

    0.7078
    -0.0011 (-0.15%)
     
  • ASX 200

    7,105.90
    -49.30 (-0.69%)
     
  • OIL

    111.45
    +1.12 (+1.02%)
     
  • GOLD

    1,845.10
    -1.20 (-0.06%)
     
  • BTC-AUD

    40,022.70
    -1,987.14 (-4.73%)
     
  • CMC Crypto 200

    617.62
    -53.38 (-7.96%)
     

Repligen Corporation to Present at 40th Annual J.P. Morgan Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

WALTHAM, Mass., Dec. 30, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtually at the 40th Annual J.P. Morgan Healthcare conference being held January 10-13. Tony J. Hunt, President and Chief Executive Officer, will present on Wednesday, January 12, 2022, at 9:45 a.m. EST.

A live webcast of the presentation will be accessible through Repligen’s Investor Relations website at www.repligen.com, and will be available for replay for a limited period of time following the event.

About Repligen Corporation

Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that increase efficiencies in the process of manufacturing biological drugs. We are inspiring advances in bioprocessing for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our corporate headquarters are located in Waltham, Massachusetts, with additional administrative and manufacturing operations worldwide. The majority of our manufacturing sites are located within the U.S. (California, Massachusetts, New Hampshire, New Jersey and New York), and outside of the U.S. we have sites in Estonia, France, Germany, Ireland, the Netherlands and Sweden. For more information about the company, including Repligen news releases, see our website at www.repligen.com. Follow us on LinkedIn and Twitter.

Repligen Contact:
Sondra S. Newman
Global Head of Investor Relations
(781) 419-1881
investors@repligen.com


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting